Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 377131
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ISIS 377131 is a second-generation antisense oligonucleotide drug developed to target the glucocorticoid receptor (GCCR). By inhibiting the production of this receptor, ISIS 377131 aims to reduce glucocorticoid action, which in turn is expected to lower blood glucose levels, improve lipid profiles, and decrease body fat. The drug was initially developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and was part of a collaboration with Ortho-McNeil (a Johnson & Johnson company) for metabolic diseases such as type 2 diabetes. The compound entered preclinical development with the goal of advancing into clinical trials for metabolic indications[4][5][7][8].
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ISIS 377131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 377131.